Douglas Wentzel focuses his practice on patent and trade secret litigation. Doug has successfully represented clients in district courts across the country and before the International Trade Commission (ITC) and Patent Trial and Appeal Board (PTAB). His cases have covered a broad spectrum of technologies, including wearable health devices, minimally invasive heart repair devices, respiratory therapy products, automotive shock absorbers, microdermabrasion systems, and more. Additionally, Doug has experience litigating design patents.
Doug is also a registered patent attorney and has experience drafting and prosecuting patent applications through allowance before the U.S. Patent and Trademark Office.
Doug holds a leadership position in the Young Lawyers Division of the Federal Bar Association’s Orange County Chapter. He has also provided pro bono legal services, including by representing a veteran in an appeal before the U.S. Court of Appeals for Veterans Claims.
Doug received his B.S. in Civil Engineering from Drexel University, where he graduated summa cum laude and collaborated in designing an 18-story proposed addition to a university dormitory. He received his J.D. with honors from the University of Pennsylvania Law School, where he founded a program to help engineering students incorporate intellectual property considerations into their hypothetical start-up businesses.
- Stays Pending Inter Partes Review: Not in the Eastern District of Texas, 98 J. Pat. & Trademark Off. Soc'y 120 (2016)
- Uber & Alice: Could One Patent Really Take Down this Ridesharing Giant?, 98 J. Pat. & Trademark Off. Soc'y 86 (2016)
Editor and Contributor, KnobbeMedical.com Blog
- AI & the FDA
- Developments in Patent Disputes Between Apple and Alivecor
- Apple Watch Found to Infringe AliveCor ECG Patents
- Medical device innovations and IP: A strategy is everything.
- BioNTech to Ship Modular mRNA Vaccine Factory to Rwanda
- AI and Cancer Diagnostics
- Federal Circuit Reverses District Court’s Decision Based on On-Sale Bar (Junker v. Medical Components, Inc.)
- FDA Seeks $7.2 Billion Budget for 2024
- FDA: Approval for Novel Medical Devices Remains a High Priority, Despite COVID-19
- FDA Breakthrough Device Designation for Biology-Guided Radiotherapy (‘BgRT’) Device
- Alpha Tau Receives FDA Breakthrough Device Designation for Alpha DaRT Treatment of GBM
- Medical Device Trade Secret Not Publicly Disclosed via Patenting, Displaying, and Selling Covered Product, 7th Cir. Affirms
- FDA Taking Steps to Prevent Future Medical Device Shortages
- Boston Scientific To Acquire Blood Clot Removal Tech Company Devoro Medical
- Stryker to Acquire Surgical Smoke Evacuator Company SafeAir
- Materialise Receives First-Ever 510(k) Clearance for Anatomical Model 3D Printing Software
- FDA Issues Final Guidance on Software as a Medical Device
- Testing of Jenex TherOZap™ Device Set to Begin
Editor and Contributor, Knobbe Martens Litigation Blog